Results of Research on Identification of Covid-19 Viruses Utilizing Advantest's nanoSCOUTER™ Fine Particle Measurement Instrument Published in Nature Communications
TOKYO, June 30, 2021 (GLOBE NEWSWIRE) -- Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) has announced that the results of a clinical study on the identification of COVID-19 viruses using the company's nanoSCOUTER™ fine particle measurement instrument were published in Nature Communications, a peer-reviewed scientific journal, on June 17th1. In the study, 100 saliva samples (50 negative for Covid-19 and 50 positive) were measured and analyzed within 5 minutes each. Sensitivity (the ability of the test to correctly identify positive samples) of 90% and specificity (the ability of the test to correctly identify negative samples) of 96% were achieved.
A research group of the Institute of Scientific and Industrial Research at Osaka University is studying virus testing methods using the AI-based particle identification system developed by Aipore Inc.2 and the nanoSCOUTER™. The method used in the just-published study identifies viral particles by passing them through a nanoscale hole, through which a microcurrent is passed, and applying AI machine-learning to the highly accurate current waveform thus obtained. The results of this research3 can be expected to facilitate immediate diagnoses in hospitals as well as viral screening for large gatherings. In addition, machine-learning can be applied to many types of viruses, enabling early detection of novel pathogens.
The nanoSCOUTER™ is a lightweight, desktop-sized fine particle measurement instrument that utilizes a precise nanopore (nanometer-scale pore) sensor module made with semiconductor manufacturing processes and Advantest's proprietary microcurrent measurement technology. It measures the quantity and particle size of fine particles on the order of 100 nanometers, such as viruses, exosomes4, and liposomes5, with great speed and accuracy. In addition, when the nanoSCOUTER™ is used in conjunction with Aipore Inc.'s AI-based particle identification system, it is possible to quickly identify the type of particles detected. At the present time, the product is a scientific instrument, not an approved medical device.
Rapid and accurate testing methods, along with vaccines and therapeutic agents, are important measures for prevention of Covid-19 spread. Based on Advantest's corporate mission of "enabling leading-edge technologies," the company will strive to further develop this technology so that the nanoSCOUTER™ can contribute to solving these vital issues.
1 "Combining machine learning and nanopore construction creates an artificial intelligence nanopore for coronavirus detection," Masateru Taniguchi, Shohei Minami, Chikako Ono, Rina Hamajima, Ayumi Morimura, Shigeto Hamaguchi, Yukihiro Akeda, Yuta Kanai, Takeshi Kobayashi, Wataru Kamitani, Yutaka Terada, Koichiro Suzuki, Nobuaki Hatori, Yoshiaki Yamagishi, Nobuei Washizu, Hiroyasu Takei, Osamu Sakamoto, Norihiko Naono, Kenji Tatematsu, Takashi Washio, Yoshiharu Matsuura, and Kazunori Tomono
2 Aipore Inc. was established in 2018 as a result of the Japanese Cabinet Office's national project "Impulsing Paradigm Change through Disruptive Technologies Program (ImPACT)". Using Advantest's nanoSCOUTER™, Aipore has developed a solution for AI analysis of measurement data of bioparticles such as viruses and bacteria.
3 The Japan Agency for Medical Research and Development (AMED) subsidized this research as a part of its Reiwa 2 virus infection prevention technology development project "Research on COVID-19 test methods using nanopore technology and machine learning."
4 Exosomes: Nano-order particles secreted from cells that contain any of various biomolecules, such as proteins or nucleic acids. Exosomes hold promise as diagnostic tools in medicine.
5 Liposomes: Closed, spherical lipid bilayers, often used as vehicles for pharmaceuticals.
About Advantest Corporation
Advantest (TSE: 6857) is the leading manufacturer of automatic test and measurement equipment used in the design and production of semiconductors for applications including 5G communications, the Internet of Things (IoT), autonomous vehicles, artificial intelligence (AI), machine learning, smart medical devices and more. Its leading-edge systems and products are integrated into the most advanced semiconductor production lines in the world. The company also conducts R&D to address emerging testing challenges and applications, produces multi-vision metrology scanning electron microscopes essential to photomask manufacturing, and offers groundbreaking 3D imaging and analysis tools. Founded in Tokyo in 1954, Advantest is a global company with facilities around the world and an international commitment to sustainable practices and social responsibility. More information is available at www.advantest.com.
Shin-Marunouchi Center Building
1-6-2 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Contact: Hiroki Yanagita, PR Section
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e5d9f459-637f-4ddd-8d99-d16403668dd2To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
RCI Banque : Rci Bank and Services Enters the Car Subscription Market With the Acquisition of Bipi27.7.2021 08:45:00 CEST | Press release
RELEASE July, 27 2021 RCI BANK AND SERVICES ENTERS THE CAR SUBSCRIPTION MARKET WITH THE ACQUISITION OF BIPI In July 2021, RCI Bank and Services, the Renault Group's automotive captive, acquired Bipi, a multi-brand platform that is a reference in car subscription offers for used vehicles, a growing segment. RCI Bank and Services will support Bipi to accelerate its growth and to open new markets, together with Bipi’s current supply partners and in conjunction with RCI Bank and Services’ dealership partners. Through this acquisition, RCI Bank and Services will extend its range of flexible all-inclusive products with multi-brand subscriptions dedicated to used vehicles. Bipi will also enable the design of subscription formulae for Mobilize's activities, in order to meet the new expectations of car drivers. Car subscription represents a market of the future which meets new uses by motorists and customers of car manufacturers. This investment and the integration of Bipi within RCI Bank and S
Ahold Delhaize share buyback update27.7.2021 08:00:00 CEST | Press release
Zaandam, the Netherlands, July 27, 2021 – Ahold Delhaize has repurchased 253,889 of Ahold Delhaize common shares in the period from July 19, 2021 up to and including July 23, 2021. The shares were repurchased at an average price of € 25.49 per share for a total consideration of € 6.5 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020. The total number of shares repurchased under this program to date is 22,071,395 common shares for a total consideration of € 512.9 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2021/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company27.7.2021 07:01:34 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 27, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2021. Business highlights Daridorexant for the treatment of insomnia under review with US FDA, EMA, and SwissmedicNine scientific presentations for daridorexant shared at SLEEP 2021Ponesimod to treat relapsing forms of multiple sclerosis was approved by the US FDA and the European Commission, Idorsia receives first income from the revenue-sharing agreement in respect to ponesimodClazosentan NDA for the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) submitted to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in March 2021“SOS-AMI” Phase 3 registration study with selatogrel in suspected acute myocardial infarction (AMI) initiated in June 2021Phase 2 study with ACT-539313 for binge eating disorder initiated in March 2021Results for MODIFY Phase 3 study with lucerastat for Fabry
Hyloris to Report 2021 Half-Year Results on 4 August 202127.7.2021 07:00:00 CEST | Press release
Liège, Belgium – 27 July 2021 –Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial results and to provide a business update. The presentation will be followed by a live Q&A session. The webcast may be accessed on the Events page of the company’s website or by clicking here. To participate in the Q&A session of the conference call, please dial one of the following numbers, ten minutes prior to the start of the live webcast: Belgium +32 2 79 338 47 France +33 1 70 700 781 Netherlands + 31 20 795 6614 United Kingdom +44 2071 928 338 United States +1 646 741 3167 Confirmation code 2687826 Following the call, a replay of the webcast will be available on the events page of the Hyloris website. About Hyloris Phar
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor27.7.2021 07:00:00 CEST | Press release
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation)i; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Jersey City, N.J., Geneva, Switzerland, July 27, 2021 - Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatme
Wereldhave N.V.: Results H1 202127.7.2021 07:00:00 CEST | Press release
Key items Major step in phasing out France: sold four out of six French assets for € 305mBenelux disposal program finalized, Koningshoek sold above book value LTV down to 46% - pro-forma for four asset French disposal 42%Dutch valuations stabilizing for the first time in nine valuation roundsAs a result of disposals, outlook 2021 direct result now at € 1.75 - 1.85 per shareOutlook direct result 2022 reiterated at € 1.40 - € 1.50 per share; to be followed by 4 - 6% annual growthDividend guidance 2021 minimum € 1.00 per share Attachment Wereldhave pr 2021-H1 - vFINAL
Leasinvest Real Estate SA: Publication of a transparency notification26.7.2021 18:00:00 CEST | Press release
PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 26 July 2021 issued by AG Insurance, shows that both a passive threshold overrun and a drop below the minimum threshold took place, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AG Insurance in Leasinvest Real Estate has therefore decreased to 2.58% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun - Drop below the minimum threshold NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress Ageas SA/NV Rue du Marquis 1, 1000